Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
pharmaceutical investing Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada
Helix BioPharma Announces the Signing of a Non-Binding Letter of Intent With ProMab Biotechnologies to Develop Cell Based Therapies
Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology Scientific Presentation at the Medical University of Warsaw
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
